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Abstract
A new metalloendopeptidase was purified to apparent homogeneity
from a homogenate of normal human liver using successive steps of
chromatography on DEAE-cellulose, hydroxyapatite and Sephacryl
S-200. The purified enzyme hydrolyzed the Pro7-Phe8 bond of brady-
kinin and the Ser25-Tyr26 bond of atrial natriuretic peptide. No cleav-
age was produced in other peptide hormones such as vasopressin,
oxytocin or Met- and Leu-enkephalin. This enzyme activity was
inhibited by 1 mM divalent cation chelators such as EDTA, EGTA and
o-phenanthroline and was insensitive to 1 µM phosphoramidon and
captopril, specific inhibitors of neutral endopeptidase (EC 3.4.24.11)
and angiotensin-converting enzyme (EC 3.4.15.1), respectively. With
Mr 85 kDa, the enzyme exhibits optimal activity at pH 7.5. The high
affinity of this endopeptidase for bradykinin (Km = 10 µM) and for
atrial natriuretic peptide (Km = 5 µM) suggests that it may play a
physiological role in the inactivation of these circulating hypotensive
peptide hormones.
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The circulating peptide hormones brady-
kinin (BK) and atrial natriuretic peptide
(ANP) are very powerful vasodilators that
may participate in the physiological control
of arterial pressure (1-5). In the blood, BK is
generated from circulating high- and low-
molecular-weight kininogens chiefly by
plasma kallikein (4), and ANP is secreted
primarily by atrial myocytes in response to
local wall stretching (5). Therefore, inacti-
vation of these peptides by the action of
degrading enzymes could be involved in the
regulation of blood pressure (6,7). Circulat-
ing BK may be inactivated by a variety of
peptidases including aminopeptidases, car-
boxypeptidases N and M, angiotensin-con-
verting enzyme (ACE; EC 3.4.15.1), neutral
endopeptidase (NEP; EC 3.4.24.11) and a
liver bradykinin-inactivating endopeptidase
similar to the thimet-endopeptidase (EC
3.4.24.15) (4,6,7). Circulating ANP may be
inactivated by NEP and receptor-mediated
clearance. However, several lines of evi-
dence suggest that the metabolism of BK and
ANP in vivo is not yet completely under-
stood, and that other metabolic pathways
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may also participate in their physiologial
inactivation. Thus, although several studies
have shown that coadministration of NEP
and clearance receptor inhibitors produces a
greater diuresis, natriuresis and depressor
arterial pressure response, probably reflect-
ing accumulation of endogenous ANP in
target tissues (8-12), these responses were
not sustained (13,14). Furthermore, the lack
of therapeutic efficacy in long-term treat-
ment for hypertension by these inhibitors
suggests that ANP may also be inactivated
by other important elimination pathways
(10,14). Finally, new ANP-degrading en-
zymes which are resistant to NEP inhibitors
were isolated from vascular smooth muscle
(15), bovine kidney (16) and human neuro-
blastoma (17).
In the present study, a new metalloen-
dopeptidase which hydrolyzes BK and ANP
with Km values at micromolar concentra-
tions was purified and characterized from
the homogenate of normal human liver.
The livers were obtained from three ap-
parently normal subjects (6 to 8 h after death
in traffic accidents) aged 20 to 30 years, and
kept at -80oC, homogenized in 4 volumes (w/
v) of 50 mM Tris-HCl, pH 7.5, and centri-
fuged at 25,000 g for 60 min at 4oC. The
pellet was discarded and the supernatant was
exhaustively dialyzed against the same buf-
fer as used for liver homogenization. A vol-
ume of 1 liter of the dialyzed supernatant
was applied to a DEAE-Trisacryl column
(2.6 x 50 cm; Pharmacia, Uppsala, Sweden)
equilibrated with 50 mM Tris-HCl, pH 7.5,
at a flow rate of 85 ml/h. After sample appli-
cation, the column was developed with step
gradients of 50 mM Tris-HCl, pH 7.5, con-
taining NaCl at the following concentra-
tions: 50, 100, 150, 300 and 1000 mM. The
fractions eluted with 50 mM NaCl contain-
ing the enzyme activity were pooled and
concentrated to 8 ml in a dialysis tube under
reduced pressure. This sample was exhaus-
tively dialyzed against 10 mM potassium
phosphate, pH 7.5, and applied to a hy-
droxyapatite column (2.5 x 10 cm; IBF,
Villeneuve-La-Garenne, France) equilibrated
with the same buffer. The column was eluted
with a 10-500 mM potassium phosphate gra-
dient, pH 7.5, at a flow rate of 28 ml/h.
Enzymatically active fractions were pooled,
concentrated and exhaustively dialyzed
against 50 mM Tris-HCl, pH 7.5. Finally,
this sample was further fractionated on a
Sephacryl S-200 column (2 x 160 cm;
Pharmacia) equilibrated against the same
buffer as used for dialysis and developed at a
flow rate of 50 ml/h. Fractions containing
enzyme activity were concentrated to 10 ml
and stored at 4oC. Under these conditions,
the purified enzyme was stable for over 2
months. A summary of the purification pro-
cedure is shown in Table 1. The enzyme
activity was monitored using as substrate the
intramolecularly quenched fluorogenic pep-
tide derived from BK, containing the o-
aminobenzoyl (Abz) and ethylenediamine
2,4-dinitrophenyl (EDDnp) groups at the
amino- and carboxyl-terminal amino acid
residues, Abz-Arg-Pro-Pro-Gly-Phe-Ser-Pro-
Phe-Arg-EDDnp, as previously described
(18,19). Protein content was evaluated by
the method of Bradford (20).
The purity of the enzyme was demon-
strated by analytical polyacrylamide gel elec-
trophoresis: i) under nondenaturing condi-
tions, showing a single band of protein which
coincided with the enzyme activity, and ii)
Table 1 - Purification of human liver metalloendopeptidase.
The enzyme activity was determined in 10-µl aliquots from each chromatography step
using Abz-R-P-P-G-F-S-P-F-R-EDDnp as substrate in a final volume of 500 µl 50 mM
Tris-HCl buffer, pH 7.5, at 37oC. Hydrolysis of the substrate was monitored by measur-
ing the fluorescence at lem = 420 nm and lex = 320 nm in a Shimadzu Model F 2000
spectrofluorometer.
Step Total protein Total activity Specific activity Purification Yield
(mg) (nmol/h) (nmol h-1 mg-1) (fold) (%)
Homogenate 23478 21168 0.90 1 100
Supernatant 1826.07 8674.80 4.75 5.3 40.98
DEAE-Trisacryl 504.34 5030.40 9.97 11.1 23.76
Hydroxyapatite 0.86 112.15 130.40 145 0.52
Sephacryl S-200 0.34 78.67 231.38 257 0.37
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under denaturing conditions (heating at
100oC in the presence of 1% SDS and 10%
ß-mercaptoethanol), also showing a single
protein band with an apparent Mr of 85 kDa
(data not shown).
The effects of various classical protease
inhibitors on the enzyme activity were tested
(data not shown). The serine- (phenylmeth-
anesulfonyl fluoride, soybean trypsin inhibi-
tor, N-tosyl-l-phenylalanine chloromethylke-
tone and aprotinin), cystine- (p-chloromer-
curibenzenesulfonic acid and N-ethylmale-
imide) and carboxyl- (pepstatin and guanidyl-
ethylmercaptosuccinic acid) protease inhibi-
tors, at 1 mM concentration, did not inhibit
the enzyme activity. However, metallopro-
tease inhibitors such as EDTA, EGTA and o-
phenanthroline at 1 mM concentration fully
inhibited the enzyme activity, suggesting that
it is a metalloendopeptidase. Furthermore,
phosphoramidon and captopril, specific in-
hibitors of neutral endopeptidase (EC
3.4.24.11) and angiotensin-converting en-
zyme (EC 3.4.15.1), respectively, did not
inhibit enzyme activity at micromolar con-
centrations.
The metalloendopeptidase hydrolyzed the
Pro7-Phe8 bond of bradykinin (Figure 1B)
and the Ser25-Tyr26 bond of atrial natriuretic
peptide (Figure 1A). The Km values for the
enzyme-catalyzed hydrolysis of BK and ANP
were 5 µM and 10 µM, respectively (data not
shown). These results indicate the high af-
finity of the metalloendopeptidase for the
peptide hormones studied, while no cleav-
age was produced in other peptide hormones
such as vasopressin, oxytocin or Met- and
Leu-enkephalin (data not shown).
The present results demonstrate that the
new metalloendopeptidase isolated from
human liver is distinct from NEP and ACE,
since specific inhibitors for both had no
effect on its activity. Furthermore, this liver
metalloendopeptidase also differs from an-
other liver bradykinin-inactivating endopep-
tidase similar to the thimet-endopeptidase
(EC 3.4.24.15) since they hydrolyze distinct
peptide bonds of BK, i.e., the Pro7-Phe8 and
Phe5-Ser6 bonds, respectively (21). Recently,
BK metabolism was investigated in the in-
tact rat liver and 7% of all BK fragments
formed during a single transhepatic passage
were from cleavage of the Pro7-Phe8 bond
(22). However, the liver endopeptidase re-
sponsible for this activity was not identified
and the new metalloendopeptidase presented
in this study may be a candidate for the
cleavage of the Pro7-Phe8 bond of BK in the
liver.
On the other hand, this liver metalloen-
dopeptidase described here showed similari-
ties with the peptide hormone-inactivating
Figure 1 - A, HPLC elution profile of atrium natriuretic peptide (ANP)(5-28) products after
hydrolysis by a purified liver metalloendopeptidase. The substrate (20 nmol) was incubated
with 15 µl of the purified enzyme in a final volume of 30 µl 50 mM Tris-HCl buffer, pH 7.5,
for 30 min at 37oC. The reaction was stopped by heating the mixture at 100oC for 5 min
followed by centrifugation at 10,000 g for 10 min. The supernatant fraction was injected
into an HPLC column (Nucleosyl 5 µm C18 145 x 4.5 mm) eluted with a 0-50% gradient of
acetonitrile containing 0.05% TFA over a period of 35 min at a flow rate of 1 ml/min.
Fragments were identified by amino acid composition: 1 and 2 are the 26-28 and 5-25
fragments of ANP(5-28), respectively. B, HPLC elution profile of bradykinin (BK) products
after hydrolysis by purified liver metalloendopeptidase. The substrate (20 nmol) was incu-
bated with 15 µl of the purified enzyme in a final volume of 30 µl 50 mM Tris-HCl buffer, pH
7.5, for 30 min at 37oC. The reaction was stopped by heating the mixture at 100oC for 5 min
followed by centrifugation at 10,000 g for 10 min. The supernatant fraction was injected
into an HPLC column (Nucleosyl 5 µm C18 145 x 4.5 mm) eluted with a 2-30% gradient of
acetonitrile containing 0.05% TFA over a period of 35 min at a flow rate of 1 ml/min.
Fragments were identified by amino acid composition: 1 and 2 are the R-P-P-G and F-S-P-F-
R fragments of BK, respectively.
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endopeptidase (PHIE) isolated from Xeno-
pus laevis skin exudate (23) and with the
metalloendopeptidase isolated from human
neuroblastoma NB-OK-1 cells (17). Both
enzymes also cleaved the Pro7-Phe8 bond of
bradykinin and the Ser25-Tyr26 bond of atrial
natriuretic peptide and exhibited the metal-
loendopeptidase character. Furthermore, the
high affinity of the liver metalloendopepti-
dase for BK (Km = 10 µM) and ANP (Km =
5 µM) is similar to that of PHIE and human
neuroblastoma endopeptidase, suggesting
that it may play a physiological role in the
degradation of these circulating hypotensive
peptide hormones. Finally, this study rein-
forces the idea that the liver, similar to the
lung and kidney, may also play an important
role in the physiological degradation of the
circulating hormones BK and ANP.
In conclusion, although further studies are
necessary to elucidate the primary structure
of this liver endopeptidase described here,
PHIE and neuroblastoma endopeptidase, these
results, taken as a whole, suggest that these
enzymes may represent members of a novel
endopeptidase family involved in the physi-
ological degradation of BK and ANP.
References
1. Ananda-Srivasta MB & Trachet GJ (1993).
Atrial natriuretic factor receptors and sig-
nal transduction mechanisms. Pharmaco-
logical Reviews, 45: 455-497.
2. Mombouli JV & Vanhoutte PM (1995). Ki-
nins and endothelial control of vascular
smooth muscle. Annual Review of Phar-
macology and Toxicology, 35: 679-705.
3. Volpe M (1991). Atrial natriuretic factor in
the control of circulatory homeostasis. In:
Adnot S, Cantin M & Pierre-Etienne C (Edi-
tors), Atrial Natriuretic Factor: Physiologi-
cal and Clinical Aspects. Flammarion
Médecine-Sciences, Paris.
4. Bhoola KD, Figueroa CD & Worthy K
(1992). Bioregulation of kinins, kallikreins,
kininogens and kininases. Pharmacological
Reviews, 44: 1-80.
5. Ruskoaho H (1992). Atrial natriuretic pep-
tide: synthesis, release, and metabolism.
Pharmacological Reviews, 44: 479-602.
6. Skidgel RA (1992). Bradykinin-degrading
enzymes: structure, function and potential
roles in cardiovascular pharmacology. Jour-
nal of Cardiovascular Pharmacology, 20
(Suppl 9): S4-S9.
7. Linz W, Wiemer G, Gohlke P, Unger T &
Schölkens BA (1995). Contribution of ki-
nins to the cardiovascular actions of angio-
tensin-converting enzyme inhibitors. Phar-
macological Reviews, 47: 25-49.
8. Koepke JP, Tyler LD, Trapani AJ, Bovy PR ,
Spear KL, Olins GM & Blaine EH (1989).
Interaction of non-guanylate cyclase-linked
atriopeptin receptor ligand and endopepti-
dase inhibitor in conscious rats. Journal of
Pharmacology and Experimental Therapeu-
tics, 249: 172-176.
9. Koepke JP, Tyler LD, Mehta PP, Olins GM,
Trapani AJ, Hartuppe DA, Bovy PR, Spear
KL & Blaine EH (1990). Atriopeptin regula-
tion and renal function in conscious spon-
taneously hypertensive rats. American
Journal of Hypertension, 3: 622-627.
10. Seymour AA, Norman JA, Assad MM,
Fennell SA, Abboa Offei B, Little DK,
Kratunis VJ, Delaney NG, Hunt JT & Di
Donato G (1991). Possible regulation of
atrial natriuretic factor by neutral endopep-
tidase 24.11 and clearance receptors. Jour-
nal of Pharmacology and Experimental
Therapeutics, 256: 1002-1009.
11. Vemulapalli S, Chiu PJ, Brown A, Griscti K
& Sybertz EJ (1991). The blood pressure
and renal responses to SCH 34826, a neu-
tral metalloendopeptidase inhibitor, and C-
ANF (4-23) in Doca-salt hypertensive rats.
Life Sciences, 49: 383-391.
12. Kukkonen P, Vuolteenaho O & Ruskoaho
H (1992). Basal and volume expansion-
stimulated plasma atrial natriuretic peptide
concentration and hemodynamics in con-
scious rats: effects of SCH 39.370, an en-
dopeptidase inhibitor, and C-ANF 4-25, a
clearance receptor ligand. Endocrinol-
ogy,130: 755-765.
13. Koepke JP, Tyler LD, Blehm DJ, Schuh JR
& Baline EH (1990). Chronic atriopeptin of
arterial pressure in conscious hypertensive
rats. Hypertension, 16: 642-647.
14. Ruskoaho H (1992). Atrial natriuretic pep-
tide: synthesis, release, and metabolism.
Pharmacological Reviews, 44: 479-602.
15. Johnson GR, Arik L, Pitts Jr B & Foster CJ
(1990). Rapid receptor mediated catabo-
lism of 125I-atrial natriuretic factor by vas-
cular endothelial cells. Biochemical Jour-
nal, 268: 771-776.
16. Toll L, Brandt SR, Olsen CM, Judd AK &
Almquist RG (1991). Isolation and charac-
terization of a new atrial peptide-degrading
enzyme from bovine kidney. Biochemical
and Biophysical Research Communica-
tions, 175: 886-893.
17. Delport C, Carvalho KM, Leseney AM,
Winand J, Christophe J & Cohen P (1992).
A new metalloendopeptidase from human
neuroblastoma NB-OK-1 cells which inacti-
vates atrial natriuretic peptide by selective
cleavage at the Ser123-Phe124 bond. Bio-
chemical and Biophysical Research Com-
munications, 182: 158-164.
18. Chagas JR, Juliano L & Prado ES (1990).
Intramolecular quenched fluorogenic tet-
rapeptide substrate for tissue and plasma
kallikreins. Analytical Biochemistry, 191:
419-425.
19. Oliveira MCF, Hirata IY, Chagas JR,
Boschov P, Gomes RAS, Figueredo AFS &
Juliano L (1992). Intramolecularly
quenched fluorogenic peptide substrate
for human renin. Analytical Biochemistry,
203: 39-46.
20. Bradford MM (1976). A rapid and sensitive
method for the quantitation of microgram
quantities of protein utilizing the principle
of protein-dye binding. Analytical Biochem-
istry, 72: 248-254.
21. Molina HM, Carmona AK, Kouyoumdjian
M, Borges DR & Juliano L (1996). Liver
bradykinin-inactivation-endopeptidase is
similar to the metalloendopeptidase (EC
3.4.24.15). Immunopharmacology, 32:
176-179.
22. Griswold JA, Beall CV, Backer Jr CR, Little
GH & Behal FJ (1996). Bradykinin metabo-
lism in the liver and lung of the rat. Journal
of Surgery Research, 66: 12-20.
23. Carvalho KM, Joudiou C, Bousseta H,
Leseney AM & Cohen P (1992). A peptide
hormone-inactivating endopeptidase in Xe-
nopus laevis skin secretions. Proceedings
of the National Academy of Sciences, USA,
89: 84-88.
